New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
14:42 EDTALNY, NVS, TKMR, ARWRAlnylam slips after Novartis reportedly cuts back RNAi development
Shares of Alnylam (ALNY) are lower in afternoon trading after a biotech focused newsletter reported that its partner, pharmaceutical giant Novartis (NVS), confirmed plans to "significantly reduce" its ribonucleic acid interface, or RNAi, research efforts. WHAT'S NEW: FierceBiotech reported earlier today that Novartis has decided to significantly cut back its once-ambitious RNAi research efforts, citing ongoing problems associated with delivering these therapies and the small number of relevant targets they could target. A total of 26 Novartis staffers were working full-time on the RNAi program full time, which grew out of a partnership with Alnylam, the report noted. OTHERS TO WATCH: Tekmira Pharmaceuticals (TKMR), like Alnylam, is focused on advancing ribonucleic acid interference therapeutics. Arrowhead Research (ARWR) is another biopharmaceutical company developing RNAi therapeutics. PRICE ACTION: In afternoon trading, Alnylam shares are down 4.5% to $52.58, Tekmira's stock is down nearly 16% to $15.49, and Arrowhead shares are off 3% to $12.71. Shares of Novartis are up about 1% to $83.48.
News For ALNY;NVS;TKMR;ARWR From The Last 14 Days
Check below for free stories on ALNY;NVS;TKMR;ARWR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 27, 2014
17:49 EDTTKMRGSK, Shire rumored to be interested in Tekmira, Daily Mail says
GlaxoSmithKline (GSK) and Shire (SHPG) are rumored to be interested in a bid for Tekmira (TKMR), reports Daily Mail. Tekmira could be a value to potential suitors, capitalized at approximately GBP 400M and the company could cost over GBP 1B in a takeover, Daily Mail adds. Reference Link
08:02 EDTALNYAlnylam receives notice of allowance from USPTO for new patent
Subscribe for More Information
August 26, 2014
07:31 EDTARWRArrowhead Research volatility at low end of one-year range
Subscribe for More Information
August 22, 2014
10:06 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: AMPE FOLD GME YOKU SPLS DKS WUBA ARWR ACHN
August 21, 2014
09:16 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
August 20, 2014
14:11 EDTTKMRTekmira lipid nanoparticle targeting Marburg virus highlighted in journal
Subscribe for More Information
12:06 EDTNVSNovartis treatment for pigmented villonodular synovitis gets orphan designation
According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link
11:42 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
08:07 EDTALNYAlnylam receives USPTO notice of allowance for new patent
Alnylam Pharmaceuticals announced that the United States Patent and Trademark Office has issued a Notice of Allowance for claims in the Tuschl et al. patent application 13/725,262. The ’262 patent application includes newly allowed claims directed to compositions that mediate RNAi, and comprising a double-stranded molecule with up to 25 base pairs and at least one nucleotide analogue. Specifically, the newly allowed patent application broadly covers small interfering RNA molecules of various designs, including so-called “dicer substrate” RNAi triggers (Amarzguioui et al., Nat Protoc. 2006;1(2):508-17; Rose et al., Nucleic Acids Res. 2005 Jul 26;33(13):4140-56) and double-stranded, RNAi-mediating molecules containing moieties that include “unlocked nucleobase analogs” amongst other naturally or non-naturally occurring nucleotide analogues. The allowed claims of the Tuschl ’262 patent application, as well as other granted, Alnylam-owned or -licensed patents, in aggregate broadly cover compositions, methods, and uses of RNAi therapeutics.
05:17 EDTNVSNovartis provides drug candidate compounds to TB Alliance
Subscribe for More Information
August 19, 2014
15:50 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
10:42 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
05:11 EDTNVSGamida Cell announces investment, option agreement with Novartis
Subscribe for More Information
August 18, 2014
10:57 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
10:01 EDTTKMROn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:46 EDTTKMRTekmira initiated with an Outperform at Leerink
Subscribe for More Information
07:35 EDTNVSApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information
August 15, 2014
10:41 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: ARWR ICPT UVXY MNKD KING VIX SVXY VXX RAX OPK
August 14, 2014
11:46 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
07:24 EDTALNYAlnylam to hold a roundtable webinar
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use